Fig. 3
From: CRISPR/Cas9 application in cancer therapy: a pioneering genome editing tool
CRISPR/Cas9 application for manufacture of next-generation CAR-T cells. Knockout (KO), T cell receptor (TCR), chimeric antigen receptor (CAR), human leukocyte antigen (HLA), granulocyte–macrophage colony-stimulating factor (GM-CSF), programmed cell death protein 1 (PD1 or PDCD1), lymphocyte activating gene 3 (LAG-3), transforming growth factor-beta receptor (TGF-βR), diacylglycerol (DAG)